Table 3.
Risk ratios for clinical outcomes according to quartiles of ANGPTL8
| Outcome | Control | Diabetes | |||||
|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 1 | Model 2 | Model 3 | ||
| Primary outcome | |||||||
| Death | Q1 (Reference) | 1 | 1 | 1 | 1 | 1 | 1 |
| Q2 (RR, 95% CI) | 1.50 (0.25–9.08) | 1.32 (0.21–8.52) | 1.26 (0.20–8.03) | 2.06 (0.76–5.59) | 2.61 (0.90–7.59) | 2.43 (0.83–7.16) | |
| Q3 (RR, 95% CI) | 2.54 (0.49–13.23) | 1.56 (0.28–8.70) | 1.48 (0.27–8.23) | 2.25 (0.84–6.05) | 2.06 (0.72–5.86) | 2.08 (0.72–6.02) | |
| Q4 (RR, 95% CI) | 4.67 (1.00–21.92) | 1.47 (0.28–7.64) | 1.32 (0.25–7.06) | 4.64 (1.86–11.59) | 3.59 (1.36–9.51) | 3.54 (1.32–9.50) | |
| Secondary outcomes | |||||||
| Q1 (Reference) | 1 | 1 | 1 | 1 | 1 | 1 | |
| Q2 (RR, 95% CI) | 1.44 (0.54–3.88) | 1.26 (0.46–3.42) | 1.21 (0.44–3.30) | 1.05 (0.55–2.01) | 1.07 (0.55–2.09) | 1.05 (0.53–2.06) | |
| Q3 (RR, 95% CI) | 1.45 (0.54–3.90) | 1.05 (0.38–2.87) | 1.02 (0.37–2.80) | 0.89 (0.46–1.74) | 0.75 (0.38–1.51) | 0.72 (0.35–1.45) | |
| Q4 (RR, 95% CI) | 2.57 (1.04–6.34) | 1.28 (0.48–3.40) | 1.19 (0.45–3.16) | 1.72 (0.95–3.12) | 1.30 (0.69–2.44) | 1.20 (0.63–2.28) | |
| MACE | Q1 (Reference) | 1 | 1 | 1 | 1 | 1 | 1 |
| Q2 (RR, 95% CI) | 2.30 (0.70–7.60) | 2.02 (0.61–6.73) | 1.96 (0.58–6.56) | 0.99 (0.47–2.10) | 1.05 (0.48–2.28) | 1.01 (0.46–2.21) | |
| Q3 (RR, 95% CI) | 1.78 (0.51–6.18) | 1.33 (0.38–4.70) | 1.29 (0.36–4.57) | 0.79 (0.36–1.73) | 0.65 (0.29–1.48) | 0.65 (0.29–1.49) | |
| Q4 (RR, 95% CI) | 3.70 (1.19–11.44) | 2.02 (0.61–6.72) | 1.90 (0.57–6.27) | 1.37 (0.68–2.77) | 0.99 (0.48–2.08) | 0.98 (0.46–2.09) | |
| HF | Q1 (Reference) | 1 | 1 | 1 | 1 | 1 | 1 |
| Q2 (RR, 95% CI) | 1.00 (0.06–16.02) | 1.62 (0.07–38.32) | 0.93 (0.04–23.90) | 1.20 (0.36–4.00) | 1.10 (0.32–3.78) | 1.11 (0.32–3.83) | |
| Q3 (RR, 95% CI) | – | – | – | 0.80 (0.21–3.01) | 0.62 (0.16–2.40) | 0.60 (0.15–2.40) | |
| Q4 (RR, 95% CI) | 1.00 (0.06–16.10) | 0.23 (0.01–5.84) | 0.14 (0.01–4.21) | 2.06 (0.69–6.13) | 1.39 (0.45–4.30) | 1.36 (0.43–4.32) | |
| Renal dysfunction | Q1 (Reference) | 1 | 1 | 1 | 1 | 1 | 1 |
| Q2 (RR, 95% CI) | – | – | – | 4.04 (0.45–36.50) | 4.08 (0.45–37.01) | 4.43 (0.47–41.99) | |
| Q3 (RR, 95% CI) | 1.00 (0.14–7.17) | 0.90 (0.12–6.75) | 0.92 (0.12–7.15) | 5.11 (0.59–44.13) | 4.85 (0.56–42.13) | 4.89 (0.53–44.95) | |
| Q4 (RR, 95% CI) | 1.51 (0.25–9.13) | 1.22 (0.16–9.26) | 1.05 (0.13–8.54) | 13.87 (1.80–107.12) | 12.53 (1.59–98.90) | 12.43 (1.48–104.81) | |
Model 1 was unadjusted
Model 2 was adjusted for age, sex and BMI
Model 3 was adjusted for all variables in model 2 plus HDL, LDL, TG, cholesterol, duration of diabetes and treatment of diabetes in diabetes group
MACE new-onset major adverse cardiovascular events, HF hospitalization for heart failure